Features of course and prevalence of COVID-19 among cancer patients in different countries
https://doi.org/10.33667/2078-5631-2023-10-47-50
Abstract
Relevance. SARS-CoV-2 and the disease it caused, COVID-19, became the reason of pandemic that changed the entire life of mankind once and for all. In the fist months, due to the lack of reliable data on this virus, experts could not even imagine how this situation would affect cancer patients. With the accumulation of experience in working with these patients in the conditions of the COVID-19 pandemic, articles summarizing information about the incidence of new coronavirus infection (NCI) and its course in cancer patients began to appear in medical publications. Up-to-date information on this topic is presented in this review.
Target. The study of the prevalence and features of the course of COVID-19 based on the analysis of current scientifi publications on this topic.
Results. The course of COVID-19 depends on many factors, including age, gender, comorbidity, ECOG status, recent cytotoxic chemotherapy, and the type of solid tumor.
Conclusions. Due to the absence of a register of the incidence of COVID-19 in Russia, cancer patients do not have a complete understanding of how the tumor process proceeds after recovery from NCI. This requires further research and in-depth analysis.
About the Authors
N. O. YuldashevaRussian Federation
Yuldasheva Natalia O., oncologist.
Ufa
D. D. Sakaeva
Russian Federation
Sakaeva Dina D., DM Sci (habil.), professor
Ufa
R. I. Kunafia
Russian Federation
Kunafia Regina I., head of Oncological Dept of Antitumor Drug Therapy No. 1.
Ufa
References
1. Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020; 150: 1–9. https://doi:10.1016/j.critrevonc.2020.102972
2. Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020; 17 (3): 519–527. https://doi: 10.20892/j.issn.2095–3941.2020.0289
3. Madan A, Siglin J, Khan A. Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020; 9 (24): 9205–9218. https://doi: 10.1002/cam4.3534
4. Gulati S, Muddasani R, Gustavo Bergerot P, Pal SK. Systemic therapy and COVID 19: Immunotherapy and chemotherapy. Urol Oncol. 2021; 39 (4): 213–220. https://doi:10.1016/j.urolonc.2020.12.022
5. Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M, Toraih EA, Saba N, Safah H, Duchesne J, Kandil E. C 6Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: Risk, clinical features, and management. Cancer Biol Med. 2020; 17 (3): 519–527. https://doi:10.20892/j.issn.2095–3941.2020.0289
6. Strang P, Hedman C, Adlitzer H, Schultz T. Dying from cancer with COVID-19: Age, sex, socio-economic status, and comorbidities. Acta Oncol. 2021; 60 (8): 1019–1024. https://doi:10.1080/0284186X.2021.1934536
7. Ullgren H, Camuto A, Rosas S, Pahnke S, Ginman B, Enblad G, Glimelius I, Fransson P, Friesland S, Liu LL. Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: A Swedish cohort study. Acta Oncol. 2021; 60 (11): 1459–1465. https://doi:10.1080/02841 86X.2021.1958005
8. Cavalcanti IDL, Soares JCS. Impact of COVID-19 on cancer patients: A review. Asia Pac J Clin Oncol. 2021; 17 (3): 186–192. https://doi:10.1111/ajco.1 3445
9. Kuderer, Nicole M et al. Clinical impact of COVID-19 on patients with cancer (CCC 19): A cohort study. The Lancet. 2020; 10241: 1907–1918. https://doi:10.1016/S 0140–6736(20)31187–9
10. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (12): 343–346. https://doi:10.15585/mmwr.mm6912e2
11. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium. Annals of Oncology. 2021; 32 (6): 787–800. https://doi:10.1016/j.annonc.2021.02.024
12. Zylberman M, Díaz-Couselo FA, Irrazabal C, Flagel S, Custidiano R, Racciopi A, Nicolini C, Bachetti P, Rébora J, Manzano N, Tavella M, Valle S, Noro L, Halac S, Cassal E, Paganini L, Aguirre M, Dictar M. Evolución clínica de pacientes internados con cáncer e infección por COVID-19 [Clinical outcomes in cancer patients hospitalized with COVID-19]. Medicina (B Aires). 2021; 81 (5): 695–702.
13. Фатеева А. В. COVID-19 у онкологических пациентов в Приморском крае: заболеваемость и летальность. Тихоокеанский медицинский журнал. 2020; 4 (82): 5–9. Fateeva A. V. COVID-19 in cancer patients in Primorsky Krai: Morbidity and mortality. Pacifi Medical Journal. 2020; 4 (82): 5–9.
14. Одилов А. А., Волков А. В., Цимбалист Н. С., Бабиченко И. И. Частота онкологических заболеваний среди 397 пациентов, умерших от COVID-19. Злокачественные опухоли. 2020; 3S 1: 129–130.
15. Odilov A. A., Volkov A. V., Zimbalist N. S., Babichenko I. I. Incidence of cancer among 397 patients who died from COVID-19. Malignant Tumors. 2020; 3S 1: 129–130.
16. Каприн А. Д., Хороненко В. Э., Захаренкова Ю. С., Гамеева Е. В. Опыт лечения онкологических больных в условиях пандемии COVID-19. Анестезиология и реаниматология. 2021; 2: 117–123. https://doi.org/10.17116/anaesthesiology2021021117
17. Kaprin A. D., Khoronenko V. E., Zakharenkova Yu.S., Gameeva E. V. Experience in the treatment of cancer patients during the COVID-19 pandemic. Anesthesiology and Resuscitation. 2021; 2: 117–123. https://doi.org/10.17116/anaesthesiology2021021117
Review
For citations:
Yuldasheva N.O., Sakaeva D.D., Kunafia R.I. Features of course and prevalence of COVID-19 among cancer patients in different countries. Medical alphabet. 2023;(10):47-50. (In Russ.) https://doi.org/10.33667/2078-5631-2023-10-47-50